NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Mirum Pharmaceuticals, Inc. MIRM
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$521.3M
▲ 54.7% vs FY2024
EPS · FY25
$-0.47
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-8.6%
Net margin · FY25
-4.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 521.3M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 4 cents on every revenue dollar this year.
Per share
USD -0.47
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-8.6%
Return on equity, FY2025
ROE
Operating margin-4.2%
Net margin-4.5%
Return on assets-3.1%
Each USD of equity lost 9 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+89.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years+74.3%
Change, 10 years—
The share count grew 74% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 842.8M
total assets, end of FY2025
Total assetsUSD 842.8M
EquityUSD 314.7M
CashUSD 296.7M
Current ratio2.67×
Equity funds 37% of total assets.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.5
0.3
0.2
0.1
0.0
0.0
·
Operating income $B
−0.0
−0.1
−0.1
−0.1
−0.2
−0.1
−0.1
EBITDA $B
0.0
−0.1
−0.1
−0.1
−0.2
−0.1
−0.1
Income tax $B
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.1
−0.2
−0.1
−0.1
−0.1
−0.1
EPS, diluted $
−0.47
−1.85
−4.00
−4.02
−2.77
−4.09
−4.58
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−8.6
−37.1
−83.7
−103.5
−57.5
−68.3
−93.0
Shares out B
0.05
0.05
0.05
0.04
0.03
0.03
0.02
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
23 of 23
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed